In this PLoS Medicine editorial, the editors review progress toward the journal’s goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project — a “comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors,” a PLoS press release writes. “By prioritizing studies in areas that contribute most substantially to the global burden of ill-health and premature mortality, PLoS Medicine, as an open-access journal, can specifically ensure that this important research is disseminated and reused widely,” the press release states (1/31).
In this New York Times opinion piece, Paul Farmer, chair of the department of global health and social medicine at Harvard Medical School and a co-founder of Partners in Health, examines the importance of the Global Fund to Fight AIDS, Tuberculosis and Malaria as it faces a “serious financial shortfall,” writing, “Beyond AIDS, the Global Fund is currently the largest donor in the world for tuberculosis and malaria programs. … The question is not whether the Global Fund works, but how to ensure it keeps working for years to come.”
In this post in the Center for Global Development’s (CGD) “Rethinking U.S. Foreign Assistance” blog, Connie Veillette, director of CGD’s rethinking U.S. foreign assistance initiative, highlights two recent posts by CGD’s Amanda Glassman and Nandini Oomman on the future of the Global Health Initiative (GHI). She writes, “With the Appropriations Committee weighing in by requiring a status report by mid-February on transitioning GHI to USAID, it is no understatement that the GHI is at an important juncture. Declining budgets for foreign assistance will also require new thinking on where the U.S. provides assistance and for what purpose” (1/31).
“The Global Fund to Fight Aids, Tuberculosis and Malaria has proved to be one of the world’s most important and innovative multilateral funding agencies,” a Financial Times editorial states. Therefore, “[t]he abrupt reshuffle of top management last week” â€“ with the resignation of Executive Director Michel Kazatchkine and the appointment of General Manager Gabriel Jaramillo â€“ “must not distract attention from its achievements over the past decade, which on their own justify further donor support,” the editorial continues. “[T]here is a need to re-examine the agency’s management and operations, particularly when squeezed donors are seeking better value for money,” and that involves “scrutinizing grant applications to ensure its stretched finances go to the neediest: those with fewest resources, the highest disease burden, and policies that do most to prevent and treat infection,” the editorial states.
“The Global Fund’s drive to ensure sustainability and efficiency means that it may not be able to meet its commitments to combat disease, says Laurie Garrett,” a senior fellow for global health at the Council on Foreign Relations, in Nature’s “World View” column. Citing his resignation letter, Garrett discusses the “the political struggle” that led Michel Kazatchkine to step down as executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria last week and writes, “It is a classic battle of titans, pitting urgency against long-term sustainability. … Kazatchkine essentially conceded victory to the forces for sustainability.”
In this post on the Center for Global Development’s (CGD) “Global Health Policy” blog, Amanda Glassman, a research fellow and director of global health policy at CGD, explains why the banking background of the new general manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gabriel Jaramillo, “should serve him well.” She says that obtaining the highest health return on investment “requires a fundamental rethink of the organization’s role as a commissioner of or payer for health services and, ultimately, health outcomes. Instead of a passive cashier, the fund can become an active and strategic investor in the shared enterprise of producing health results. And that is a banker’s business” (1/30).
Pharmaceutical company heads and global health leaders gathered at a conference on Monday in London to announce the formation of a large public-private partnership to fight neglected tropical diseases (NTDs) and endorse the “London Declaration on Neglected Tropical Diseases” (.pdf), in which they pledged to work together and track progress. The following is a summary of two opinion pieces and a blog post in response to the news.
Last week, the Global Fund to Fight AIDS, Tuberculosis and Malaria celebrated its 10-year anniversary. The following are summaries of two opinion pieces written in recognition of this milestone.
In this AlertNet commentary, GAVI Alliance CEO Seth Berkley discusses how “public-private partnership is part of the GAVI Alliance’s formula for success that has helped countries to immunize 325 million children in our first 10 years, saving more than 5.5 million lives.” Writing last week from the World Economic Forum in Davos, Switzerland, Berkley says, “In fact, public-private partnerships are part of what brings me to Davos this week.”
Ellen Johnson Sirleaf, president of Liberia and the new chair of the African Leaders Malaria Alliance (ALMA), writes in a Huffington Post opinion piece about Africa’s efforts in the fight against malaria. “Supported by the lessons learned from the decade to ‘roll back malaria,’ which produced a 33 percent decline in malaria deaths in Africa between 2000 and 2010, 41 African presidents have now signed on to end deaths from the disease in their home countries as part of [ALMA],” she writes. But “[d]espite this encouraging progress, much work remains to be done,” she continues.